Key to efficient hardware emulation is an efficient mapping to the underlying CPU’s opcodes. Here one is free to target ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based ...
Samantha Hicks is affiliated with the South Carolina Association of Financial Aid Administrators as current member and President-Elect and the Southern Association of Student Financial Aid ...
When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a new layer of information,” specifically ...
GOG's preservation program is a commitment by the distribution service to ensure that classic PC games included in the program will run on your Windows machine no matter what. This doesn't mean ...
TL;DR: GOG enhances its consumer-friendly platform by expanding the Preservation Program with 16 classic PC games, ensuring compatibility with modern hardware and operating systems. The program ...
States are banning cellphones in schools, but do these policies actually work to improve student behavior and achievement? A pair of research projects led by noted academic scholars provide some ...
General Motors Co. is scrapping plans for a factory in Detroit as part of a broader decision to end development of hydrogen fuel cells for everyday drivers, the automaker said Friday. Salaried workers ...
Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.
Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Japanese pharma giant ...
This article was produced for ProPublica’s Local Reporting Network in partnership with The Current. Sign up for Dispatches to get stories like this one as soon as they are published. Update, Sept. 24, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback